320 related articles for article (PubMed ID: 25542271)
1. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
[TBL] [Abstract][Full Text] [Related]
2. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
5. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
6. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
7. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
8. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
11. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
13. P95 HER2 fragments and breast cancer outcome.
Tural D; Akar E; Mutlu H; Kilickap S
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1089-96. PubMed ID: 24968823
[TBL] [Abstract][Full Text] [Related]
14. De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance.
Veeraraghavan J; De Angelis C; Reis-Filho JS; Pascual T; Prat A; Rimawi MF; Osborne CK; Schiff R
Breast; 2017 Aug; 34 Suppl 1(Suppl 1):S19-S26. PubMed ID: 28687441
[TBL] [Abstract][Full Text] [Related]
15. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
Bedard PL; de Azambuja E; Cardoso F
Curr Cancer Drug Targets; 2009 Mar; 9(2):148-62. PubMed ID: 19275756
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
17. Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.
Creedon H; Byron A; Main J; Hayward L; Klinowska T; Brunton VG
Biochem Soc Trans; 2014 Aug; 42(4):822-30. PubMed ID: 25109964
[TBL] [Abstract][Full Text] [Related]
18. Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.
Puglisi F; Minisini AM; De Angelis C; Arpino G
Drugs; 2012 Jun; 72(9):1175-93. PubMed ID: 22686613
[TBL] [Abstract][Full Text] [Related]
19. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
20. HER2 expression and PI3K-Akt pathway alterations in gastric cancer.
Sukawa Y; Yamamoto H; Nosho K; Ito M; Igarashi H; Naito T; Mitsuhashi K; Matsunaga Y; Takahashi T; Mikami M; Adachi Y; Suzuki H; Shinomura Y
Digestion; 2014; 89(1):12-7. PubMed ID: 24458107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]